Nerai pioneers novel highly personalized CRISPR proteins to deliver lifelong cures for diseases beyond the reach of current genome editing. By fusing AI with programmable biology, its editors redefine what is achievable in the safety, efficiency, and targetability of genetic medicine. With lead programs targeting multi-billion markets in rare liver and eye disease and strong biopharma traction for its platform technology, Nerai is poised to become a key European-based player in vivo genome editing.
Venture Leaders Biotech 2025 connects Swiss science with the US biotech market (venturelab.swiss)
Nerai Bioscience: The Venture Leader Biotech redefining genetic medicine (venturelab.swiss)
18 startups selected for >>venture>> final pitches (startupticker.ch)
Venture Leaders Biotech 2025 kick off at Swiss Biotech Day ahead of Boston roadshow (venturelab.swiss)
Venture Leaders Biotech 2025 cohort revealed (startupticker.ch)
Venture Leaders Biotech 2025: 10 innovative startups selected for Boston roadshow (venturelab.swiss)
Top3 finalist of >>venture>>
Nerai is incorporated - long live Nerai!
Innosuisse Innovation Project
Venture Kick Stage 3
GRS Innobooster
UZH fellowship